Tamoxifen: The drug that came in from the cold

L. Hughes-Davies; C. Caldas; G. C. Wishart

doi:10.1038/sj.bjc.6605231

Tamoxifen: The drug that came in from the cold

L. Hughes-Davies
, C. Caldas
, G. C. Wishart

Research output: Contribution to journal › Short survey › peer-review

35 Scopus citations

Abstract

Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

Original language	English
Pages (from-to)	875-878
Number of pages	4
Journal	British Journal of Cancer
Volume	101
Issue number	6
DOIs	https://doi.org/10.1038/sj.bjc.6605231
State	Published - 15 Sep 2009
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adjuvant therapy
Breast cancer
Oestrogen receptor
Post-menopausal
Tamoxifen; aromatase inhibitors

Access to Document

10.1038/sj.bjc.6605231

Cite this

@article{fd7cdf55e46c4819b0606839c07213ee,

title = "Tamoxifen: The drug that came in from the cold",

abstract = "Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.",

keywords = "Adjuvant therapy, Breast cancer, Oestrogen receptor, Post-menopausal, Tamoxifen; aromatase inhibitors",

author = "L. Hughes-Davies and C. Caldas and Wishart, \{G. C.\}",

year = "2009",

month = sep,

day = "15",

doi = "10.1038/sj.bjc.6605231",

language = "אנגלית",

volume = "101",

pages = "875--878",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - Tamoxifen

T2 - The drug that came in from the cold

AU - Hughes-Davies, L.

AU - Caldas, C.

AU - Wishart, G. C.

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

AB - Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

KW - Adjuvant therapy

KW - Breast cancer

KW - Oestrogen receptor

KW - Post-menopausal

KW - Tamoxifen; aromatase inhibitors

UR - https://www.scopus.com/pages/publications/70249103772

U2 - 10.1038/sj.bjc.6605231

DO - 10.1038/sj.bjc.6605231

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???

C2 - 19672259

AN - SCOPUS:70249103772

SN - 0007-0920

VL - 101

SP - 875

EP - 878

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -

Tamoxifen: The drug that came in from the cold

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this